Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010475.pdf
0001558370-16-010475.rtf
0001558370-16-010475.xls
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001047469-16-017071.pdf
0001047469-16-017071.rtf
0001047469-16-017071.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010368.pdf
0001558370-16-010368.rtf
0001558370-16-010368.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-032359.pdf
0001179110-16-032359.rtf
0001179110-16-032359.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010378.pdf
0001558370-16-010378.rtf
0001558370-16-010378.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010318.pdf
0001558370-16-010318.rtf
0001558370-16-010318.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010326.pdf
0001558370-16-010326.rtf
0001558370-16-010326.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010336.pdf
0001558370-16-010336.rtf
0001558370-16-010336.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-010300.pdf
0001558370-16-010300.rtf
0001558370-16-010300.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-16-032094.pdf
0001179110-16-032094.rtf
0001179110-16-032094.xls